Cargando…
Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases
Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they pot...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961589/ https://www.ncbi.nlm.nih.gov/pubmed/36839853 http://dx.doi.org/10.3390/pharmaceutics15020532 |
_version_ | 1784895792162537472 |
---|---|
author | Schnichels, Sven Simmang, David Löscher, Marina Herrmann, Andreas de Vries, Jan Willem Spitzer, Martin S. Hurst, José |
author_facet | Schnichels, Sven Simmang, David Löscher, Marina Herrmann, Andreas de Vries, Jan Willem Spitzer, Martin S. Hurst, José |
author_sort | Schnichels, Sven |
collection | PubMed |
description | Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they potentially cause serious side effects, e.g., infections, bleeding within the eye or retinal detachment, especially when performed on a monthly basis, thus decreasing the injection frequency and lowering the desired drug dose. Therefore, a sustained released at the region of interest with a sustained release is desired. Recently, novel lipid-DNA nanoparticles (NPs) were shown to be an efficient drug delivery platform to the anterior segment of the eye. In this study, we investigated the distribution and tropism of the NPs when applied intravitreally, as a potential medication carrier to the posterior part of the eye. This technology is perfectly suited for the delivery of low molecular weight drugs to the back of the eye, which so far is greatly hindered by fast diffusion rates of the free drugs in the vitreous body and their intrinsically low retainability in ocular tissue. Excellent biodistribution, adherence and presence for up to five days was found for the different tested nanoparticles ex vivo and in vivo. In conclusion, our lipid-DNA based nanocarrier system was able to reach the retina within minutes and penetrate the retina providing potentially safe and long-term carrier systems for small molecules or nucleotide-based therapies. |
format | Online Article Text |
id | pubmed-9961589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99615892023-02-26 Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases Schnichels, Sven Simmang, David Löscher, Marina Herrmann, Andreas de Vries, Jan Willem Spitzer, Martin S. Hurst, José Pharmaceutics Article Retinal eye diseases are the leading cause of blindness in the Western world. Up to date, the only efficient treatment for many retinal diseases consists of invasive intravitreal injections of highly concentrated drugs. Despite the fact that these injections are unpleasant for the patients, they potentially cause serious side effects, e.g., infections, bleeding within the eye or retinal detachment, especially when performed on a monthly basis, thus decreasing the injection frequency and lowering the desired drug dose. Therefore, a sustained released at the region of interest with a sustained release is desired. Recently, novel lipid-DNA nanoparticles (NPs) were shown to be an efficient drug delivery platform to the anterior segment of the eye. In this study, we investigated the distribution and tropism of the NPs when applied intravitreally, as a potential medication carrier to the posterior part of the eye. This technology is perfectly suited for the delivery of low molecular weight drugs to the back of the eye, which so far is greatly hindered by fast diffusion rates of the free drugs in the vitreous body and their intrinsically low retainability in ocular tissue. Excellent biodistribution, adherence and presence for up to five days was found for the different tested nanoparticles ex vivo and in vivo. In conclusion, our lipid-DNA based nanocarrier system was able to reach the retina within minutes and penetrate the retina providing potentially safe and long-term carrier systems for small molecules or nucleotide-based therapies. MDPI 2023-02-04 /pmc/articles/PMC9961589/ /pubmed/36839853 http://dx.doi.org/10.3390/pharmaceutics15020532 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schnichels, Sven Simmang, David Löscher, Marina Herrmann, Andreas de Vries, Jan Willem Spitzer, Martin S. Hurst, José Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
title | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
title_full | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
title_fullStr | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
title_full_unstemmed | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
title_short | Lipid-DNA Nanoparticles as Drug-Delivery Vehicles for the Treatment of Retinal Diseases |
title_sort | lipid-dna nanoparticles as drug-delivery vehicles for the treatment of retinal diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961589/ https://www.ncbi.nlm.nih.gov/pubmed/36839853 http://dx.doi.org/10.3390/pharmaceutics15020532 |
work_keys_str_mv | AT schnichelssven lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT simmangdavid lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT loschermarina lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT herrmannandreas lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT devriesjanwillem lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT spitzermartins lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases AT hurstjose lipiddnananoparticlesasdrugdeliveryvehiclesforthetreatmentofretinaldiseases |